Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | GUCY1A1 | Q02108 | 13/20 | 0.55 |
| ▸ | GUCY1B1 | Q02153 | 13/20 | 0.55 |
| ▸ | PDE5A | O76074 | 3/20 | 0.49 |
| ▸ | BUB1 | O43683 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12298811 | 0.98 | KCNH2 (0.68) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL12298800 | 0.90 | KCNH2 (0.55) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL12298801 | 0.85 | KCNH2 (0.51) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL12299623 | 0.84 | PDE5A (0.50) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL23186727 | 0.83 | KCNH2 (0.77) | KCNH2ADORA3GUCY1A1GUCY1B1 | |
| SCHEMBL12298808 | 0.82 | PDE5A (0.52) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL23186728 | 0.82 | KCNH2 (0.72) | KCNH2ADORA3GUCY1A1GUCY1B1 | |
| SCHEMBL12299208 | 0.81 | PDE5A (0.55) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL23186714 | 0.81 | KCNH2 (0.71) | KCNH2ADORA3GUCY1A1GUCY1B1 | |
| SCHEMBL23186736 | 0.81 | KCNH2 (0.71) | KCNH2ADORA3GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130178475-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2011115804-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178475-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | KCNH2 2088/4885ADORA3 2877/4885GUCY1A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.